Actuate Therapeutics (NASDAQ:ACTU) & Psyence Biomedical (NASDAQ:PBM) Head to Head Comparison

Psyence Biomedical (NASDAQ:PBM) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Risk and Volatility

Psyence Biomedical has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500. Comparatively, Actuate Therapeutics has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500.

Earnings & Valuation

This table compares Psyence Biomedical and Actuate Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Psyence Biomedical	N/A	N/A	-$6.94 million	$25.34	0.14
Actuate Therapeutics	N/A	N/A	-$22.23 million	($0.97)	-1.05

Actuate Therapeutics is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

77.4% of Psyence Biomedical shares are held by institutional investors. 3.6% of Psyence Biomedical shares are held by insiders. Comparatively, 58.0% of Actuate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for Psyence Biomedical and Actuate Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1	0	0	0	1.00
Actuate Therapeutics	1	0	3	0	2.50

Actuate Therapeutics has a consensus target price of $13.67, suggesting a potential upside of 1,239.87%. Given Actuate Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Actuate Therapeutics is more favorable than Psyence Biomedical.

Profitability

This table compares Psyence Biomedical and Actuate Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
Actuate Therapeutics	N/A	-430.93%	-180.86%

Summary

Psyence Biomedical beats Actuate Therapeutics on 7 of the 11 factors compared between the two stocks.

About Psyence Biomedical

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

About Actuate Therapeutics

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.